Eli Lilly's Retevmo met the primary endpoint in a Phase III lung cancer trial, Merck discontinued its TROP2 ADC MK-6837, and a Tango/Revolution combination showed benefit in pancreatic cancer.
Tango Therapeutics said it plans to start a pivotal 300-patient randomized vopimetostat trial in second-line pancreatic cancer this year after FDA interactions. The company also reported early combination enrollment with daraxonrasib and zoldonrasib and said more monotherapy and combination data are expected later this year.
Drug Hunter's most-accessed resources, reviews, and case studies in 2025 reflected key trends in drug discovery, including the rise of oral macrocycles, advances in new modalities, and the shift from biologics to small molecules in immunology.
